An observational study in Community Acquired Pneumonia (CAP), sponsored by Societa Italiana di Pneumologia. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-18.
Sponsored by Societa Italiana di Pneumologia · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Community-Acquired Pneumonia with a site in Italy — 6 open to participants now, 6 under way, 2 of them phase 3. Community-Acquired Pneumonia · Italy.
Among the 17 studies in Community-Acquired Pneumonia with a site in Italy, this one is the 4th largest by planned enrollment of the 11 observational ones that give a count, is one of 3 that started in 2025, is one of 11 observational ones, and was the 14th registered.
325 studies on the registry are indexed under Community-Acquired Pneumonia; 77 are open to participants now.
Browse Community-Acquired Pneumonia studies →6 of the 17 studies in Community-Acquired Pneumonia with a site in Italy are open now. Recruiting first, the newest first:
Azienda Ospedaliero-Universitaria Careggi · Sites in Italy
Ages 18–90
University of Oxford · Sites in Italy, Belgium, Estonia and 13 more countries
Ages 0+
University of Trieste · Sites in Italy
Ages 18+
UMC Utrecht · Sites in Italy, United States, Australia and 26 more countries
Ages 28 days+
Joan Sabater-Riera · Sites in Italy, Croatia, France and 3 more countries
Ages 65+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 41 Community-Acquired Pneumonia studies recruiting now, 29 (71%) set no upper age limit and 9 (22%) stop at 75 or younger; 13 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,298 is above the median of 650 across 111 observational studies indexed under Community-Acquired Pneumonia.
Median enrollment 507 across the 6 interventional studies, 500 across the 11 observational. Of the 8 that completed or were terminated, 2 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 17 have an industry lead sponsor. The 10 most frequent:
Societa Italiana di Pneumologia is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Societa Italiana di Pneumologia has 1 study filed under Community-Acquired Pneumonia — fewer than ten, so there is no comparison to draw.
1 of the studies in Community-Acquired Pneumonia with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07070284Joan Sabater-RieraESCAPE10: Epidemiology, Risk Factors, and Outcomes of Severe Community-acquired Pneumonia in Elderly Patients Acquired Pneumonia in Elderly Patients | 2026-11-30 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies in Community-Acquired Pneumonia with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This multicentric, prospective study aims at:
evaluating the prevalence, etiology, characteristics, and 1one-year outcomes of immunocompromised patients hospitalized for Community-Acquired Pneumonia (CAP); conducting biochemical, microbiological and genetic analysis on collected samples.
Primary endpoint:
Collection of in- hospitalisation mortality for all causes in immunocompromised patients with CAP enrolled.
Secondary endpoints:
Collection of data on admission and during hospitalisation to evaluate clinical response to empirical treatments (including antibiotic therapy) related to severity of disease and microbiological etiology.
Prevalence of cardiovascular events and all-cause mortality during hospitalization or after discharge.
Biochemical, microbiological and genetic analysis on collected samples.
Immunosuppressed patients with Community-Acquired Pneumonia will be enrolled during hospitalization in Italian Pneumology, Infectious Diseases and Emergency Departments selected on their specific experteeze and know-how. Upon discharge, patients will be followed up at 30 days, 3 months, 6 months and 12 months after discharge.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Hospitalized patients with a confirmed diagnosis of Community-Acquired Pneumonia (CAP) characterized by at least one of the following risk factors for :
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In-hospital mortality for all causes in immunocompromised patients with CAP enrolled in the study.
Recording in-hospital mortality for all causes in immunocompromised patients with CAP enrolled in the study.
Time frame: During hospitalization corresponding to study enrollment (1 day to 2 weeks of hospitalization on average)
Time to clinical stability
Time to clinical stability calculated as the number of days from the date of admission to the date that the patient meets clinical stability criteria, up to 8 days. Clinical stability is defined as follows: improved clinical signs (improved cough and shortness of breath), lack of fever for at least 8 hours, improving leukocytosis (decreased at least 10% from the previous day), and tolerating oral intake.
Time frame: DAY 1 to 8
Mortality for all causes in immunocompromised patients with CAP
Mortality for all causes in immunocompromised patients with CAP enrolled in the study.
Time frame: 30 days, 3 months, 6 months and 12 months after hospital discharge.
New hospitalizations in immunocompromised patients with CAP.
Recording new hospitalizations in immunocompromised patients with CAP enrolled in the study.
Time frame: 30 days, 3 months, 6 months and 12 months after hospital discharge.
Prevalence of cardiovascular events in immunocompromised patients with CAP.
Prevalence of cardiovascular events in immunocompromised patients with CAP enrolled in the study.
Time frame: 30 days, 3 months, 6 months and 12 months after hospital discharge.
Length of hospital stay (days)
Time frame: Through hospital discharge, ranging from 1 day to 2 weeks
ICU admission %
Time frame: During hospitalization corresponding to study enrollment (1 day to 2 weeks of hospitalization on average)
Need for mechanical ventilation %
Time frame: During hospitalization (1 day to 2 weeks on average)
Lenght of mechanical ventilation (Hours)
Time frame: During hospitalization (1 day to 2 weeks on average)
Rate of antibiotic therapy modification (%)
Time frame: During hospitalization (1 day to 2 weeks on average)
Subsequent re-admission within 1 year
Time frame: Within 365 days after hospital discharge
Characterization of Microbiological Etiology Using 16S rRNA Sequencing and Whole-Genome Sequencing
Microbiological analysis will be performed on sputum, bronchoalveolar lavage (BAL), and bronchial aspirate (BAS) samples. The 16S rRNA sequencing will be conducted to evaluate the relative abundance of identified bacterial genera (percentage/total) and to calculate alpha diversity indices, including Shannon and Equitability indices. For samples where bacterial strains are isolated, whole-genome sequencing (WGS) will be performed to identify and study resistance, virulence, and pathogenicity genes. These findings will be correlated with clinical data to provide insights into microbiological etiology. Data will be summarized as relative abundances, diversity indices, and the presence/absence of key genomic features.
Time frame: Through study completion, for up to 4 years
Started Aug 2025 (actual). Primary completion is estimated for Dec 2028, 40 months after the start.
Of 38 observational studies under Community-Acquired Pneumonia, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 57. This study's planned 40 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Community-Acquired Pneumonia →
Societa Italiana di Pneumologia